Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The IMID Forum
Author Interview: Professor Valentino Paci, April 2026
Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure
Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
Author Interview: Professor Helena Marzo-Ortega, March 2026
Get summaries like this every morning.
Free AI-powered recaps of The IMID Forum and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.